SCHEMBL411201

SCHEMBL411201

CC(C)(C)OC(=O)N1CCCN(c2ccc(C(C)(C)C)cc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.61
ALDH1A1 P00352 3/20 0.61
LMNA P02545 2/20 0.61
GPR119 Q8TDV5 7/20 0.54
SMN1; SMN2 Q16637 5/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
CYP2C19 P33261 1/20 0.54
HTT P42858 4/20 0.53
KDM4E B2RXH2 1/20 0.53
NAMPT P43490 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
PDK2 Q15119 1/20 0.50
CKS1B P61024 1/20 0.50
SKP1 P63208 1/20 0.50
SKP2 Q13309 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12781689 0.94 MAPT (0.67) MAPTALDH1A1LMNAGPR119SMN1; SMN2
SCHEMBL5231271 0.90 MAPT (0.67) MAPTALDH1A1LMNAGPR119SMN1; SMN2
SCHEMBL13281422 0.88 MAPT (0.62) MAPTALDH1A1LMNAGPR119SMN1; SMN2
SCHEMBL5231173 0.88 GPR119 (0.70) MAPTALDH1A1LMNAGPR119SMN1; SMN2
SCHEMBL5573222 0.87 MAPT (0.76) MAPTALDH1A1LMNAGPR119SMN1; SMN2
SCHEMBL3194630 0.86 MAPT (0.61) MAPTALDH1A1LMNAGPR119SMN1; SMN2
SCHEMBL1257264 0.86 MEN1 (0.70) MAPTALDH1A1LMNAGPR119SMN1; SMN2
SCHEMBL5230610 0.86 ALDH1A1 (0.61) MAPTALDH1A1LMNAGPR119SMN1; SMN2
SCHEMBL5236861 0.86 MAPT (0.61) MAPTALDH1A1LMNAGPR119SMN1; SMN2
SCHEMBL5235594 0.86 GPR119 (0.69) MAPTALDH1A1LMNAGPR119SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096524-B2 Anthelmintic agents and their use INTERVET INTERNATIONAL B.V. (NL) 2015-08-04 US disclosed
US-9096524-B2 Anthelmintic agents and their use INTERVET INTERNATIONAL B.V. (NL) 2015-08-04 US disclosed
US-9096524-B2 Anthelmintic agents and their use INTERVET INTERNATIONAL B.V. (NL) 2015-08-04 US disclosed
EP-2408742-B1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INT BV (NL) 2014-09-03 EP disclosed
EP-2408742-B1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INT BV (NL) 2014-09-03 EP disclosed
EP-2408742-A1 ANTHELMINTIC AGENTS AND THEIR USE Intervet International B.V. (NL) 2012-01-25 EP disclosed
US-20110319393-A1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INTERNATIONAL B.V. (NL) 2011-12-29 US disclosed
US-20110319393-A1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INTERNATIONAL B.V. (NL) 2011-12-29 US disclosed
US-20110319393-A1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INTERNATIONAL B.V. (NL) 2011-12-29 US disclosed
WO-2010115688-A1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INTERNATIONAL B.V. (NL) 2010-10-14 WO disclosed
WO-2010115688-A1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INTERNATIONAL B.V. (NL) 2010-10-14 WO disclosed
US-20070219234-A1 Thienopyridine Derivatives SANKYO COMPANY, LIMITED (JP) 2007-09-20 US disclosed
EP-1764367-A1 THIENOPYRIDINE DERIVATIVES Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319393-A1 ANTHELMINTIC AGENTS AND THEIR USE ACHE, ABCB11, MPO MAPT 1648/4885ALDH1A1 864/4885LMNA 3826/4885
US-20070219234-A1 Thienopyridine Derivatives RASGRP1, NRAS, HRH3 MAPT 4452/4885ALDH1A1 1073/4885LMNA 4549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.